全球多重检测市场

预计到 2030 年，全球多重检测市场规模将达到 60 亿美元

全球多重检测市场规模预计在2024年为41亿美元，预计到2030年将达到60亿美元，2024年至2030年的复合年增长率为6.4%。报告分析的细分市场之一——耗材——预计复合年增长率为6.9%，到分析期结束时规模将达到37亿美元。分析期间内，设备细分市场的复合年增长率预计为5.4%。

美国市场规模估计为 11 亿美元，中国市场预期复合年增长率为 9.6%

预计到2024年，美国多重检测市场规模将达11亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到14亿美元，在2024-2030年的分析期间内，复合年增长率为9.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为3.5%和6.1%。在欧洲，预计德国市场的复合年增长率为3.8%。

全球多重分析市场－主要趋势与驱动因素摘要

什么是多重分析以及它们如何用于研究和诊断？

多重检测是一种先进的诊断工具，可同时检测和分析单一样本中的多种生物标记（例如蛋白质、基因和其他分子）。此类检测广泛应用于科学研究、临床诊断和药物开发，以更准确、更有效率地分析复杂的生物过程或检测疾病。与一次测量一种分析物的传统检测不同，多重检测透过同时评估多个标靶提供全面的概览，从而节省时间、降低成本并提高数据吞吐量。此类检测在肿瘤学、免疫学和感染疾病等领域至关重要，了解多种生物标记有助于更准确的诊断和製定个人化治疗策略。

哪些技术进步将形塑多重分析的未来？

生物技术和分子诊断技术的进步正在推动多重检测变得更加灵敏、准确和可扩展。次世代定序仪(NGS) 技术和微阵列平台的开发显着提高了同时分析大量基因和蛋白质数据的能力。此外，萤光和化学冷光检测方法的进步提高了多重检测的灵敏度和准确度，使得低浓度生物标记的检测成为可能。与人工智慧 (AI) 和机器学习的结合实现了更先进的数据分析，帮助研究人员和临床医生更有效地解读复杂的检测结果。这些技术创新正在扩大多重检测在伴随诊断、生物标记发现和个人化医疗等领域的应用。

个人化医疗的转变如何推动多重检测的需求？

个人化医疗日益成为趋势，即根据患者独特的基因、分子和环境特征为其量身定制治疗方案，这推动了对多重检测的需求。这些检测使医疗保健提供者能够同时分析多种生物标记物，从而更全面地了解患者的健康和疾病状态。例如，在肿瘤学领域，多重检测可用于识别可指南标靶治疗的特定突变或基因表现。在单次检测中检测和监测多种疾病相关标记的能力还可以同时评估多种结果，从而提高药物开发和临床试验的效率。这种对更个人化和精准医疗保健的追求，是多重检测市场的主要成长动力。

推动多重检测市场成长的关键因素有哪些？

多重检测市场的成长受到多种因素的推动，包括分子诊断的进步、慢性病盛行率的上升以及对个人化医疗的不断增长的需求。高通量平台和增强检测方法的开发等技术创新正在提高多重检测的准确性并使其应用范围更广。癌症和其他复杂疾病的发生率不断上升也推动了这些检测在研究和临床环境中的应用，在这些环境中，了解多种生物标记对于诊断和治疗至关重要。此外，伴随诊断的扩展（使用多重检测为患者匹配特定治疗方法）进一步推动了需求。多重检测在药物开发的应用日益增多，尤其是在生物标记主导的新药临床试验中，也是市场成长的主要因素。

部分

产品（耗材、仪器、软体和服务）；类型（蛋白质检测、核酸检测、细胞检测）；最终用户（製药和生物技术公司、医院和研究机构、参考实验室、其他最终用户）

调查企业范例（共11家值得关注的企业）

• Abcam PLC
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Illumina, Inc.
• Luminex Corporation
• Merck KgaA
• Meso Scale Diagnostics, LLC.
• Olink
• Qiagen NV
• Quanterix Corporation
• Randox Laboratories Ltd.
• Seegene, Inc.
• Thermo Fisher Scientific, Inc.

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业SLM 的典型规范，而是建立了一个从全球专家收集的内容库，其中包括视讯录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地、进出口状况（成品和原始OEM）预测其竞争态势的变化。这种复杂且多面向的市场动态预计将以多种方式影响竞争对手，包括销货成本成本 (COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

• 市场概览
• 主要企业
• 市场趋势和驱动因素
• 全球市场展望

第三章市场分析

• 美国
• 加拿大
• 日本
• 中国
• 欧洲
• 法国
• 德国
• 义大利
• 英国
• 西班牙
• 俄罗斯
• 其他欧洲国家
• 亚太地区
• 澳洲
• 印度
• 韩国
• 其他亚太地区
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中东
• 伊朗
• 以色列
• 沙乌地阿拉伯
• 阿拉伯聯合大公国
• 其他中东地区
• 非洲

第四章 竞赛

Global Multiplex Assays Market to Reach US$6.0 Billion by 2030

The global market for Multiplex Assays estimated at US$4.1 Billion in the year 2024, is expected to reach US$6.0 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 5.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 9.6% CAGR

The Multiplex Assays market in the U.S. is estimated at US$1.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Multiplex Assays Market - Key Trends & Drivers Summarized

What Are Multiplex Assays and How Are They Used in Research and Diagnostics?

Multiplex assays are advanced diagnostic tools that allow the simultaneous detection and analysis of multiple biological markers (such as proteins, genes, or other molecules) in a single sample. These assays are widely used in research, clinical diagnostics, and drug development to analyze complex biological processes or detect diseases with higher accuracy and efficiency. Unlike traditional assays that measure one analyte at a time, multiplex assays provide a comprehensive overview by assessing multiple targets simultaneously, thus saving time, reducing costs, and increasing data throughput. These assays are essential in fields like oncology, immunology, and infectious diseases, where understanding multiple biomarkers can lead to more accurate diagnoses and personalized treatment strategies.

What Technological Advances Are Shaping the Future of Multiplex Assays?

Advancements in biotechnology and molecular diagnostics are transforming multiplex assays, making them more sensitive, accurate, and scalable. The development of next-generation sequencing (NGS) technologies and microarray platforms has significantly enhanced the ability to analyze large volumes of genetic and protein data simultaneously. Furthermore, advances in fluorescent and chemiluminescent detection methods have improved the sensitivity and precision of multiplex assays, allowing for the detection of lower concentrations of biomarkers. Integration with artificial intelligence (AI) and machine learning is enabling more sophisticated data analysis, helping researchers and clinicians interpret complex assay results more effectively. These technological innovations are expanding the use of multiplex assays in areas such as companion diagnostics, biomarker discovery, and personalized medicine.

How Is the Shift Toward Personalized Medicine Driving the Demand for Multiplex Assays?

The growing trend toward personalized medicine, which tailors treatments to individual patients based on their unique genetic, molecular, and environmental profiles, is significantly boosting the demand for multiplex assays. These assays enable healthcare providers to analyze multiple biomarkers at once, offering a more comprehensive understanding of a patient’s health and disease status. In oncology, for example, multiplex assays are being used to identify specific mutations or gene expressions that can guide targeted therapies. The ability to detect and monitor several disease-related markers in a single test is also enhancing the efficiency of drug development and clinical trials, where multiple outcomes can be evaluated simultaneously. This push toward more personalized and precise healthcare is a major growth driver for the multiplex assays market.

What Are the Key Growth Drivers in the Multiplex Assays Market?

The growth in the multiplex assays market is driven by several factors, including advancements in molecular diagnostics, the rising prevalence of chronic diseases, and the increasing demand for personalized medicine. Technological innovations, such as the development of high-throughput platforms and enhanced detection methods, are making multiplex assays more accurate and accessible for a wider range of applications. The growing incidence of cancer and other complex diseases is also pushing the adoption of these assays in research and clinical settings, where understanding multiple biomarkers is critical for diagnosis and treatment. Additionally, the expansion of companion diagnostics, where multiplex assays are used to match patients with specific therapies, is further driving demand. The increasing use of multiplex assays in pharmaceutical development, especially in the context of biomarker-driven drug trials, is another significant factor contributing to market growth.

SCOPE OF STUDY:

The report analyzes the Multiplex Assays market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Consumables, Instruments, Software & Services); Type (Protein Assays, Nucleic Acid Assays, Cell-Based Assays); End-Use (Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

• Abcam PLC
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Illumina, Inc.
• Luminex Corporation
• Merck KgaA
• Meso Scale Diagnostics, LLC.
• Olink
• Qiagen NV
• Quanterix Corporation
• Randox Laboratories Ltd.
• Seegene, Inc.
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Global Economic Update
  • Multiplex Assays - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Demand for High-Throughput Diagnostic Testing Drives Adoption of Multiplex Assays
  • Rising Prevalence of Chronic and Infectious Diseases Expands Addressable Market for Multiplex Assays in Diagnostics
  • Increasing Focus on Personalized Medicine and Biomarker Discovery Strengthens Business Case for Multiplex Assays
  • Growth in Pharmaceutical R&D and Drug Development Fuels Demand for Multiplex Assays in Drug Screening
  • Technological Advancements in Multiplex Assay Platforms Propel Innovation in Precision Diagnostics
  • Rising Use of Multiplex Assays in Oncology Expands Opportunities for Cancer Diagnosis and Treatment
  • Increasing Adoption of Multiplex Assays in Immunology Research Strengthens Market for Comprehensive Immune Profiling
  • Growth in Point-of-Care Testing Drives Demand for Rapid Multiplex Diagnostic Assays
  • Increasing Focus on Reducing Healthcare Costs and Improving Diagnostic Efficiency Expands Market for Multiplex Assays
  • Technological Advancements in Microfluidics and Lab-on-a-Chip Platforms Propel Growth in Multiplex Assay Development
  • Rising Adoption of Multiplex Assays in Vaccine Development Strengthens Business Case for High-Throughput Screening
  • Growth in Demand for Multiplex Assays in Infectious Disease Testing Expands Market for Pandemic Preparedness
  • Increasing Use of Multiplex Assays in Clinical Trials Drives Growth in Pharmaceutical and Biotechnology Applications
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Protein Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Protein Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 3: World 15-Year Perspective for Protein Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Nucleic Acid Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Nucleic Acid Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 6: World 15-Year Perspective for Nucleic Acid Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Cell-based Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Cell-based Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 9: World 15-Year Perspective for Cell-based Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 12: World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 15: World 15-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 18: World 15-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 21: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Hospitals & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Hospitals & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 24: World 15-Year Perspective for Hospitals & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 27: World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 30: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 31: World Multiplex Assays Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Multiplex Assays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 62: China Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Multiplex Assays by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
• FRANCE
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 83: France Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 110: UK Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Multiplex Assays by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
• AUSTRALIA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 167: India Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Multiplex Assays by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Multiplex Assays by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Multiplex Assays by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
• IRAN
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Multiplex Assays Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Multiplex Assays by Type - Protein Assays, Nucleic Acid Assays and Cell-based Assays Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Multiplex Assays by Type - Percentage Breakdown of Value Sales for Protein Assays, Nucleic Acid Assays and Cell-based Assays for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Multiplex Assays by Offering - Consumables, Instruments and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Multiplex Assays by Offering - Consumables, Instruments and Software & Services Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Multiplex Assays by Offering - Percentage Breakdown of Value Sales for Consumables, Instruments and Software & Services for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Multiplex Assays by End-Use - Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Multiplex Assays by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Research Institutes, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION